ArticleScientific reports2026
Physiologically relevant forms of Tc- and Re-pyrophosphate radioactive tracers and the basis of their transthyretin amyloid sensitivity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[Formula: see text]Technetium Pyrophosphate ([Formula: see text]Tc-PYP(Sn)) is a commonly used radioactive tracer, with a long history of use in diagnosing bone-related diseases and a newfound purpose in differentiating ATTR and AL amyloidoses. Despite its ubiquity, basic aspects like its composition and structure are as of yet undetermined, and its method of binding to ATTR amyloid fibrils is likewise hitherto unknown. This complicates the diagnostic process, as it introduces inexplicable losses of sensitivity in some ATTR and AL variants. In this paper we report the results of our comprehensive investigation into the physiologically active structure of Tc-PYP and its closely related, but experimentally more approachable counterpart, Re-PYP, built on a robust theoretical basis and backed up by multiple spectroscopic methods (focusing on the rhenium analogue). We conclude that the Re/Tc-PYP tracers possess a flexible geometry, but ultimately appear as octahedral Re(IV)/Tc(IV) diaqua dipyrophosphate complexes under physiological conditions, and predict that this structure is the reason for the high affinity of [Formula: see text]Tc-PYP for certain amyloids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.